A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This is a phase ll study of participants with large B Cell lymphoma previously treated with
anti-CD19 Chimeric antigen receptor (CAR-T) therapy. The purpose of the study is to to
evaluate the efficacy of zanubrutinib and tislelizumab in patients with progressive lymphoma
post anti-CD 19 CAR-T failure.